Fujinami, Robert

Fujinami, Robert is a sole proprietor providing medical expert services and case review analysis for the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP) as a prime contractor under multiple blanket purchase agreements held by the Department of Health and Human Services' Health Resources and Services Administration (HRSA). All ninety awards in the source data are prime contracts, with no subcontract footprint. The vendor operates from Emigration Canyon, Utah and competes predominantly under total small business set-asides across VICP and CICP task orders.

HRSA dominates the customer base, accounting for 86 awards and $8.5 million in combined potential value (approximately 99% of the portfolio), with the Department of Justice Civil Division placing four small awards ($39 thousand combined) for expert witness services. The vendor holds three active BPAs with HRSA: 75R60221A00043 (36 task orders, $225 thousand combined potential value), 75R60219A00030 (25 task orders, $65 thousand combined potential value), and HHSH250201400084B (20 task orders, $71 thousand combined potential value). A newly established single-award BPA awarded on May 15, 2026, carries a $7.5 million ceiling through May 14, 2031 and consolidates VICP and CICP medical expert and case review services.

Representative work includes a $37,500 BPA call from HRSA awarded August 26, 2026 for medical case review services supporting VICP adjudication (performance through July 25, 2027), a $24,375 total small business set-aside call from September 2025 for medical expert services in vaccine injury claims (multiple nomenclature variants appear in the source for this same contract vehicle), and a $14,685 firm fixed-price call from June 2022 for medical expert case review on VICP Case #18-0295. Work consists of reviewing medical records, drafting expert medical opinions, providing consultation, and offering expert testimony to support the evaluation and adjudication of vaccine injury and countermeasures injury claims.

Activity has contracted sharply in recent years—24 awards in 2021 declining to just two in 2026—reflecting the nature of individual case assignments under the VICP program structure. Only one award ($38 thousand) faces ultimate completion within the next twenty-four months, indicating minimal near-term recompete exposure but also a narrowing pipeline outside the newly established $7.5 million BPA. Combined obligated dollars total $438 thousand against $8.6 million in combined potential value, suggesting task orders issue incrementally as individual vaccine injury cases arrive for expert review rather than as upfront funding commitments.